Smart science to improve lives™


Add to favourites
Versatile and effective, PHAD acts as a TLR4 agonist to activate proinflammatory cytokines and antigen-specific effector cells.

PHAD is the first synthetic analogue of monophosphoryl lipid A (MPLA) derived from Salmonella minnesota. MPLA has been shown to be safe and effective in stimulating Th-1 type immune responses. Avanti developed PHAD as a synthetic alternative to the bacterial-derived MPLA, given its desirable vaccine design profile of low reactogenicity and high efficacy.

The interest in PHAD is a testament to its powerful immunological profile. It stimulates the immune system through the activation of toll-like receptor 4 (TLR4). This results in the production of proinflammatory cytokines, CD4+ and CD8+ T-cells.

It has been effectively employed in cancer vaccine research, and as a TLR4 agonist adjuvant in vaccine candidates, such as respiratory syncytial virus and rabies.

PHAD adjuvants can be used in combination or individually to ignite stronger immune responses as part of vaccine development.

Pre clinical research has confirmed that PHAD exhibits similar activity and safety profiles to MPLA.

Determining what adjuvant is best suited to your needs requires a discussion. Contact us to start your journey today.

Our PHAD is manufactured according to cGMP guidelines for clinical development.

How to request a sample

This is an exclusive product

Speak with an expert to request a sample

Product details

Chemical group

  • Synthetic Monophosphoryl Lipid A

Administration route

  • Vaccine adjuvant

Market application

  • Human vaccines
  • Veterinary vaccines


  • Vaccine adjuvant

Physical form

  • Powder